The duality of changes induced by USP8 mutation in corticotropinomas and alterations in the balance between proliferative and antiproliferative effects in each individual case can explain the inconsistency of clinical data obtained by researchers from CD patients with corticotropinomas with different USP8 mutation statuses [7,13,14,20,22,23,33,34]. Here, USP8 is linked to ACTH-producing pituitary gland adenoma.